State of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and Immunization

Table 6

Preventive hepatitis C virus vaccine tested in clinical trials.

Type of vaccine	Viral component	Adjuvant	Phase of clinical trial	Study population	Year	Reference
Recombinant protein	Recombinant E1 protein	Aluminum hydroxide	I	20 healthy subjects	2004	[123]
	Recombinant E1 and E2 proteins	MF59	I	60 healthy subjects	2010	[124]
	Recombinant core protein	ISCOMATRIX	I	60 healthy subjects	2009	[125]
Peptide	Five synthetic peptides derived from conserved regions of core, NS3, and NS4 proteins of HCV genotypes 1 and 2 (IC41)	Poly-L-arginine	I	128 healthy subjects	2006	[126]
	Five synthetic peptides derived from conserved regions of core, NS3, and NS4 proteins of HCV genotypes 1 and 2 (IC41)	Poly-L-arginine	I	54 healthy subjects	2010	[127]
Virally vectored	Human adenovirus rare serotype 6 (HADV6) and chimpanzee Ad 3 (ChAd3) expressing the HCV nonstructural proteins	—	I	30 healthy subjects	2012	[128]